On October 20, 2022 SYnAbs reported a research collaboration program to discover novel therapeutic antibodies against challenging G Protein Coupled Receptor (GPCR) targets (Press release, Domain Therapeutics, SEP 20, 2022, View Source [SID1234622452]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For Domain Therapeutics, this collaboration aims at diversifying its proprietary portfolio of immunotherapies with biologics to deliver therapeutic solutions against tumors triggering GPCR-mediated immunosuppression. Under the terms of the agreement, Domain Therapeutics retains exclusive worldwide rights to validate, optimize, develop and commercialize any therapeutic antibodies discovered in the course of the collaboration.
For SYnAbs, the goal is to further optimize its technologies capable of generating highly specific antibodies targeting epitopes that are difficult to express in their native and functionally active conformation.
SYnAbs approach consists in immunizing species with peptides and its proprietary syngeneic cell lines, all mixed with its in-house adjuvant in order to neutralize the immunotolerance usually developed against highly homologous transmembrane targets and benefit from a natural in-vivo maturation.
SYnAbs is also the developer of the rat-LOU species, a species known to be a high responder against haptens and which has the unique ability to naturally generate autoantibodies. This animal is already the source of several therapeutic antibodies such as Siplizumab (licensed to MedImmune, Phase III), LO-CD2b (Preclinical Tox), LO-TACT- 1, anti-CD25 (Phase I/II) and more recently SYnC3aR, a blocking mAb to hC3aR anaphylatoxin receptor.
Under the terms of the agreement, SYnAbs will utilize its know-how and proprietary technologies combined with Domain Therapeutics deep expertise in GPCRs and immuno-oncology to identify novel high-potential drug candidates. Domain will be responsible for the preclinical and clinical development of the jointly discovered antibodies and for a potential partnership with a third party company according to Domain Therapeutics strategy.